EGFR and ovarian carcinoma: Previous studies reported that SIP-SII exhibited multiple anti-tumor effects such as suppression of EGFR, FGF, and intercellular adhesion molecule (ICAM)-mediated pathways in ovarian cancer cells and epidermoid carcinoma cells [13] [15].